Filtrer vos résultats
- 3
- 2
- 1
- 3
- 1
- 1
- 1
- 3
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
|
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 YearsInflammatory Bowel Diseases, 2016, 22 (12), pp.2924-2932. ⟨10.1097/MIB.0000000000000967⟩
Article dans une revue
hal-03553388v1
|
||
|
Ustekinumab efficacy and safety in Crohn's disease patients refractory to conventional and anti-TNF therapy: a multicenter retrospective experience.10. Congress of ECCO, European Crohn's and Colitis Organisation, Feb 2015, Barcelone, Spain. pp.S37-S39, ⟨10.1093/ecco-jcc/jju027.057⟩
Communication dans un congrès
hal-03553426v1
|
||
Long-term efficacy and safety of ustekinumab in refractory Crohn's disease patients: a multicenter retrospective experience12. Congress of ECCO, European Crohn's and Colitis Organisation, Feb 2017, Barcelone, Spain
Communication dans un congrès
hal-03553341v1
|